Your browser is no longer supported. Please, upgrade your browser.
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 177 #1
CompanySignal Genetics, Inc.
IndustryMedical Laboratories & Research
Market Cap16.99MEPS (ttm)-2.72
P/E-EPS this Y-400.00%
Forward P/E-EPS next Y52.70%
PEG-EPS past 5Y0.00%
P/S4.36EPS next 5Y-
P/B0.97EPS Q/Q-125.00%
Dividend-Sales Q/Q-45.50%
Insider Own4.30%Inst Own14.00%
Insider Trans0.00%Inst Trans335.61%
Short Float4.08%EarningsMar 30
Analyst Recom2.00Target Price2.75
Avg Volume174.39K52W Range1.42 - 9.05
May-27-15 08:30AMSignal Genetics to Present at the LD Micro Invitational Conference GlobeNewswire
May-22-15 01:04PMSIGNAL GENETICS, INC. Financials
May-15-15 04:40PMSIGNAL GENETICS, INC. Files SEC form 10-Q, Quarterly Report
Signal Genetics, Inc., a commercial stage molecular genetic diagnostic company, focuses on providing diagnostic services that assist physicians in decision making for the care of patients suffering from cancer. It offers Myeloma Prognostic Risk Signature (MyPRS) test, a microarray-based gene expression profile assay to test the presence of various groups of genes that predict low or high level risk of early relapse in patients suffering from multiple myeloma. The company holds license to the intellectual property developed at Myeloma Institute for Research and Therapy in University of Arkansas for Medical Sciences. Signal Genetics, Inc. was founded in 2010 and is headquartered in Carlsbad, California.
CompanyFreeSeas Inc.
Market Cap2.30MEPS (ttm)-34.16
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-14.90%
P/S0.60EPS next 5Y-
P/B0.06EPS Q/Q-
Dividend-Sales Q/Q-44.40%
Insider Own-Inst Own0.40%
Insider Trans-Inst Trans25.68%
Short Float31.48%Earnings-
Analyst Recom-Target Price-
Avg Volume4.25M52W Range0.04 - 6.83
May-26-15 09:00AMFreeseas Enters Agreement for the Financing of Vessel Acquisition GlobeNewswire
May-08-15 04:30PMFreeSeas Announces Reverse Split of Common Stock GlobeNewswire
May-08-15 01:04PMFREESEAS INC. Financials
Nov-18-14 05:34AMForrester Advises Advertisers To Abandon Facebook Because It Is Biased Against Them
Aug-23-14 12:00PMShould so-called free apps really be labeled as free?
FreeSeas Inc., through its subsidiaries, provides drybulk shipping services. Its vessels carry various drybulk commodities, such as iron ore, grain, and coal, as well as bauxite, phosphate, fertilizers, steel products, cement, sugar, and rice. Its fleet consists of five Handysize vessels and one Handymax vessel. As of April 23, 2015, its operational fleet had approximately 148,978 deadweight tons with the average age of 17.7 years. The company was formerly known as Adventure Holdings S.A. and changed its name to FreeSeas Inc. in April 2005. FreeSeas Inc. was founded in 2004 and is based in Athens, Greece.
CompanyCheck-Cap Ltd.
IndustryMedical Laboratories & Research
Market Cap37.70MEPS (ttm)-0.74
P/E-EPS this Y0.00%
Forward P/E-EPS next Y-23.60%
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y-
P/B1.67EPS Q/Q-29.30%
Dividend-Sales Q/Q-
Insider Own-Inst Own12.80%
Insider Trans-Inst Trans-
Short Float0.00%Earnings-
Analyst Recom2.00Target Price9.00
Avg Volume18.89K52W Range2.62 - 6.30
Jun-04-15 09:15AMCheck-Cap Reports First Quarter 2015 Financial Results and Provides Corporate Update PR Newswire
May-19-15 10:37AMCheck-Cap Expands Management Team with Appointment of Bill Densel as President of U.S. Operations PR Newswire
May-15-15 05:00PMCheck-Cap Issues Reminder to Shareholders Who Purchased Units in its Initial Public Offering Regarding Long Term Incentive Warrants PR Newswire
May-12-15 09:23AMCheck-Cap to Present at the 2015 Marcum MicroCap Conference on May 28, 2015 PR Newswire
May-07-15 07:00AMCheck-Cap Announces Extraordinary General Meeting of Shareholders PR Newswire
May-04-15 07:00AMCheck-Cap to Participate in the Oppenheimer 16th Annual Israeli Conference on May 10, 2015 in Tel Aviv PR Newswire
May-01-15 08:10AMCoverage initiated on Check-Cap by Chardan Capital Markets
Apr-29-15 04:15PMCheck-Cap Ltd. Files Annual Report on Form 20-F for the Year Ended December 31, 2014 PR Newswire
Apr-27-15 07:00AMCheck-Cap Receives Notice of U.S. Patent Allowance for Proprietary Non-Invasive, Preparation-Free Capsule Endoscopy Technology PR Newswire
Mar-30-15 11:48AMCheck-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 PR Newswire
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening for precancerous polyps and colorectal cancer. Its lead product is an endoscopy capsule with a colon imaging system for colorectal cancer and pre-cancerous polyps that utilizes X-ray-based measurement technology to generate 3-dimensional imagery of the colon without cleansing or other aggressive bowel preparation. The company was founded in 2004 and is headquartered in Mount Carmel, Israel.
CompanyRCS Capital Corporation
IndustryInvestment Brokerage - National
Market Cap591.20MEPS (ttm)-5.14
P/E-EPS this Y-2.10%
Forward P/E4.33EPS next Y24.24%
PEG-EPS past 5Y0.00%
P/S0.24EPS next 5Y14.40%
P/B0.97EPS Q/Q-341.70%
Dividend9.40%Sales Q/Q128.80%
Insider Own40.60%Inst Own52.40%
Insider Trans-0.21%Inst Trans-0.04%
Short Float25.73%EarningsAug 06/b
Analyst Recom2.00Target Price13.25
Avg Volume672.82K52W Range5.87 - 24.80
Jun-30-15 04:40PMRCS Capital Summary
Jun-30-15 03:26PMRCS Capital Agrees to Covenant Modifications at The Wall Street Journal
Jun-30-15 03:10PMRCS CAPITAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial
Jun-30-15 02:22PM2:22 pm RCS Capital announces that it has agreed with its first and second lien lenders, to certain leverage ratio covenant amendments for its existing credit facilities
Jun-30-15 02:19PMRCS Capital and its Lenders Agree to Covenant Modifications PR Newswire
Jun-10-15 04:15PMAgnes Lew Honored Among Bank Investment Consultant Magazine's Top 20 Program Managers PR Newswire
Jun-08-15 08:30AMCetera Financial Institutions Welcomes Bobby Huddleston as Senior Vice President of New Business Development PR Newswire
RCS Capital Corporation engages in the independent retail advice, wholesale distribution, investment banking, capital markets, investment management, and investment research businesses. The company offers independent retail advices, financial products, and investment solutions through a network of independent channel broker-dealers and registered investment advisers; and multi-product distribution platform of direct investment program offerings to independent broker-dealers and the retail financial advisor community. It also operates as a registrar; provides record-keeping services; and executes the transfer, issuance, and cancellation of shares or other securities in connection with offerings conducted by issuers. In addition, the company provides strategic advisory services comprising advising sponsors in the structuring and development of new direct investment programs, and registered investment funds and other products; advising sponsors and companies with respect to direct investment programs; advising direct investment programs primarily for non-traded real estate investment trusts in connection with liquidity alternatives, which include listing on a national securities exchange and initial public offering transactions; and debt and equity capital raising advisory services, such as structuring, pricing, and marketing services. Further, it offers transaction management services, such as services related to offering registration and blue sky filings; regulatory advice; registration maintenance; transaction management; marketing support; due diligence advice and related meetings; events; training and education; conference management; and strategic advice. The company was formerly known as 405 Holding Corporation and changed its name to RCS Capital Corporation in February 2013. RCS Capital Corporation was incorporated in 2012 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Luxor Capital Group, LP10% OwnerApr 02Sale10.67456,9104,875,49784,979Apr 02 09:51 PM
Jones Brian DCFO & Ass. SecretaryMar 31Buy11.65390,5854,550,003496,703Apr 29 09:56 PM
Weil Edward M Jr.CEONov 18Buy12.1420,550249,4281,083,958Nov 18 02:00 PM
BROWN JEFFREY JDirectorJul 02Buy22.491,00022,4867,473Jul 03 02:30 PM
TickerAST [AMEX]
CompanyAsterias Biotherapeutics, Inc.
Market Cap172.68MEPS (ttm)-0.35
P/E-EPS this Y38.90%
Forward P/E-EPS next Y-27.80%
PEG-EPS past 5Y0.00%
P/S90.89EPS next 5Y-
P/B3.77EPS Q/Q-28.60%
Dividend-Sales Q/Q700.00%
Insider Own1.50%Inst Own9.00%
Insider Trans-Inst Trans48.67%
Short Float10.58%EarningsMay 07/a
Analyst Recom2.00Target Price15.50
Avg Volume272.43K52W Range1.51 - 15.10
Jun-09-15 04:31PMASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jun-08-15 06:30AMAsterias Biotherapeutics Announces First Patient Treated in Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury PR Newswire
Jun-01-15 06:30AMPositive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) PR Newswire
Asterias Biotherapeutics, Inc., a biotechnology company, focuses on the emerging field of regenerative medicines. It is developing pluripotent stem-cell therapeutic products in the areas of neurology and oncology. The company's product candidates include AST-OPC1, which is in Phase I/IIa clinical trial for the treatment of spinal cord injury, multiple sclerosis, and stroke; and AST-VAC2, the allogeneic dendritic cells loaded with telomerase antigen for the treatment of non-small cell lung cancer, as well as multiple cancer types, antigens, and infectious diseases. It is also developing AST-VAC1 for the treatment of prostate cancer and acute myelogenous leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is based in Menlo Park, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.
CompanyMajesco Entertainment Co.
IndustryMultimedia & Graphics Software
Market Cap14.20MEPS (ttm)-2.03
P/E-EPS this Y-18.30%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-8.30%
P/S0.99EPS next 5Y15.00%
P/B-EPS Q/Q7.10%
Dividend-Sales Q/Q-46.90%
Insider Own1.20%Inst Own4.80%
Insider Trans-2.11%Inst Trans66.38%
Short Float0.91%EarningsApr 30/a
Analyst Recom3.00Target Price1.00
Avg Volume163.91K52W Range0.55 - 2.65
Jun-17-15 08:09PM10-Q for Majesco Entertainment Co. at Company Spotlight
Jun-15-15 04:35PMMAJESCO ENTERTAINMENT CO Files SEC form 10-Q, Quarterly Report
Jun-09-15 04:20PMMAJESCO ENTERTAINMENT CO Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
May-21-15 04:51PMMAJESCO ENTERTAINMENT CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
May-05-15 05:31PMMAJESCO ENTERTAINMENT CO Files SEC form 8-K, Entry into a Material Definitive Agreement
May-03-15 08:13PM10-Q for Majesco Entertainment Co. at Company Spotlight
Apr-30-15 05:23PMMAJESCO ENTERTAINMENT CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
Apr-30-15 09:48AMMajesco Entertainment Executes Definitive Financing Documents and Retires Outstanding Warrants Marketwired
Apr-09-15 09:35AMMAJESCO ENTERTAINMENT CO Files SEC form 8-K, Other Events
Majesco Entertainment Company develops, publishes, and distributes video game products primarily for casual-game consumers worldwide. The company publishes video games for various interactive entertainment hardware platforms, including Nintendo's DS, DSi, 3DS, Wii and WiiU, Sony's PlayStation 3, Microsoft's Xbox 360 and Xbox One, and the personal computers. It also publishes games for various digital platforms consisting of Xbox Live Arcade and PlayStation Network; mobile platforms, such as the iOS and Android phones; and online platforms, including Facebook and Steam. The company sells its products primarily to large retail chains, specialty retail stores, video game rental outlets, and distributors. Majesco Entertainment Company was founded in 1998 and is based in Edison, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aronson LaurenceDirectorFeb 06Sale1.212,5003,02560,919Feb 10 05:27 PM
Grafman AllanDirectorNov 04Sale1.144,1814,76619,919Nov 06 04:02 PM
Grafman AllanDirectorAug 05Sale1.663,1165,17324,100Aug 07 06:52 PM
CompanyAdvaxis, Inc.
Market Cap638.16MEPS (ttm)-1.31
P/E-EPS this Y76.30%
Forward P/E-EPS next Y5.20%
PEG-EPS past 5Y-24.50%
P/S-EPS next 5Y-
P/B11.42EPS Q/Q-246.70%
Dividend-Sales Q/Q-
Insider Own5.40%Inst Own51.40%
Insider Trans232.17%Inst Trans72.77%
Short Float11.56%EarningsJun 12
Analyst Recom1.70Target Price25.80
Avg Volume1.90M52W Range2.50 - 30.13
Jun-17-15 08:09PM10-Q for Advaxis, Inc. at Company Spotlight
Jun-15-15 06:04AMADVAXIS, INC. Files SEC form 10-Q, Quarterly Report
Jun-02-15 04:23PMADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Jun-01-15 03:06PMAlere Inc (ALR), Lion Biotech (LBIO), Genocea Biosciences Inc (GNCA), Advaxis Inc (ADXS) Among Broadfins Top New Health Picks at Insider Monkey
Jun-01-15 07:30AMAdvaxis Announces FDA Clearance of Investigational New Drug Application for Phase 2 Study of ADXS-HPV and Incyte's epacadostat for the Treatment of HPV-Associated Early Stage Cervical Cancer PR Newswire
May-27-15 04:31PMADVAXIS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-22-15 07:30AMAdvaxis to Present at the Jefferies 2015 Global Healthcare Conference GlobeNewswire
May-21-15 07:30AMAdvaxis Appoints Fred J. Frullo Vice President, Regulatory Affairs GlobeNewswire
May-20-15 05:03PMADVAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate designed to target the PSA antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate for the treatment of Her2 expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has a clinical trial collaboration with MedImmune, LLC to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV, a cancer immunotherapy vaccine to treat patients with cervical cancer, and HPV-associated head and neck cancer. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADAGE CAPITAL PARTNERS GP LLC10% OwnerApr 30Buy19.00500,0009,500,0005,639,366May 04 04:26 PM
ADAGE CAPITAL PARTNERS GP LLC10% OwnerFeb 18Buy7.50684,7625,135,7155,139,366Feb 20 04:02 PM
CompanyEpizyme, Inc.
Market Cap988.80MEPS (ttm)-3.18
P/E-EPS this Y-659.10%
Forward P/E-EPS next Y18.60%
PEG-EPS past 5Y0.00%
P/S34.21EPS next 5Y-
P/B3.85EPS Q/Q-695.50%
Dividend-Sales Q/Q-93.30%
Insider Own34.22%Inst Own95.40%
Insider Trans0.01%Inst Trans26.00%
Short Float17.85%EarningsAug 05/b
Analyst Recom1.90Target Price38.67
Avg Volume412.04K52W Range15.51 - 40.98
Jun-29-15 04:34PMEpizyme to Present Clinical Data from Ongoing Phase 1 Dose Escalation Trial of Tazemetostat (EPZ-6438) at the European Cancer Congress Business Wire
Jun-25-15 09:30AMThe Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases
Jun-24-15 08:44AMBiotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog
Jun-23-15 11:51AMTuesday's Mid-Day Movers: Ambarella Retaliates; Sonic, BlackBerry Hit
Jun-23-15 10:56AMEdited Transcript of EPZM conference call or presentation 22-Jun-15 12:00pm GMT
Jun-23-15 08:51AMEpizyme (EPZM) Shows Strength: Stock Moves 25.2% Higher - Tale of the Tape
Jun-22-15 02:50PMEpizyme Soars On Blood-Cancer Drug Data at Investor's Business Daily
Jun-22-15 11:50AMEpizyme Lead Candidate Effective in Ongoing Cancer Study - Analyst Blog
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). The company has two HMTs inhibitors in clinical development for the treatment of patients with cancers. It is conducting a Phase I/II clinical trial of EPZ-6438, an inhibitor that targets the EZH2 HMT for the treatment of non-Hodgkin lymphoma and advanced solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors; and two Phase 1 clinical trials of EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemia with genetic alterations of the MLL gene. It has therapeutic collaborations with Celgene Corporation and Celgene International Srl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic development collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ho Peter Tai-ChingChief Development OfficerMay 05Buy16.3680013,0841,000May 06 06:03 PM
Ho Peter Tai-ChingChief Development OfficerDec 16Buy17.634007,052600Dec 18 06:34 PM
Ho Peter Tai-ChingChief Development OfficerDec 02Buy21.192004,238200Dec 04 06:17 PM
Ho Peter Tai-ChingChief Development OfficerDec 02Buy21.1680016,930400Dec 04 06:17 PM
Copeland Robert AEVP and CSONov 17Option Exercise2.1920,00043,80020,000Nov 19 05:39 PM
CompanyAmyris, Inc.
IndustrySpecialty Chemicals
Market Cap155.88MEPS (ttm)-1.35
P/E-EPS this Y100.60%
Forward P/E-EPS next Y58.20%
PEG-EPS past 5Y14.90%
P/S3.46EPS next 5Y30.00%
P/B-EPS Q/Q-414.30%
Dividend-Sales Q/Q31.70%
Insider Own22.20%Inst Own48.80%
Insider Trans-0.71%Inst Trans-0.48%
Short Float10.56%EarningsAug 06/a
Analyst Recom3.00Target Price2.25
Avg Volume163.81K52W Range1.56 - 4.50
Jun-30-15 02:57PMAmyris Surges After Total Raises Stake in Biofuel Joint Venture at Bloomberg
Jun-30-15 12:39PMAmyris, Total to Restructure Joint Venture at The Wall Street Journal
Jun-30-15 11:35AMAmyris Announces Total's Decision to Proceed With Jet Fuel Joint Venture and Plans to Restructure and Convert $175 Million of Outstanding Convertible Debt for Common Stock GlobeNewswire
Jun-29-15 09:05AMAmyris Announces Successful Completion of Volkswagen Renewable Diesel Evaluation Program GlobeNewswire
Jun-29-15 09:00AMVolkswagen Completes Successful Renewable Fuel Evaluation With Solazyme and Amyris Marketwired
Jun-25-15 03:05PMAmyris & Dinaco Announce Exclusive Re-Seller Agreement for Neossance(R) Cosmetic Ingredients in Brazil GlobeNewswire
Jun-09-15 04:07PMAMYRIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jun-09-15 08:30AMAmyris & Ipca Laboratories Ltd. Sign Letter of Intent for Development and Supply of Active Pharmaceutical Ingredients GlobeNewswire
Amyris, Inc. provides various alternatives to a range of petroleum-sourced products for the consumer care, specialty chemical, and transportation fuel markets worldwide. The company applies its industrial synthetic biology platform to design microbes and primarily yeast, as well as to convert plant-sourced sugars into renewable hydrocarbons. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and various materials for performance materials market; renewable fuels for transportation fuels market; and base oils for lubricants market. It has a collaboration partnership with Total to commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Melo JohnPresident and CEOJun 05Sale1.9620,44040,158279,666Jun 05 07:02 PM
Melo JohnPresident and CEOJun 04Sale2.0020,41840,828300,106Jun 05 07:02 PM
Melo JohnPresident and CEOJun 03Sale2.0420,41841,555320,524Jun 05 07:02 PM
Melo JohnPresident and CEOMay 12Sale2.0420,44041,659340,942May 12 09:25 PM
Melo JohnPresident and CEOMay 11Sale2.0420,41841,634361,382May 12 09:25 PM
CompanyCode Rebel Corp
IndustryApplication Software
Market Cap410.45MEPS (ttm)-0.05
P/E-EPS this Y-25.00%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S2052.26EPS next 5Y-
Dividend-Sales Q/Q95.20%
Insider Own29.00%Inst Own-
Insider Trans-Inst Trans-
Short Float0.25%Earnings-
Analyst Recom-Target Price-
Avg Volume32.12K52W Range11.97 - 44.21
May-26-15 06:00PMMaking Money With Charles Payne: 05/26/15 at Fox Business
May-24-15 08:15AMIPO Recap and Outlook for 2015 at 24/7 Wall St.
May-20-15 05:47PMSoftware Soars, But Cream Hasn't Risen To The Top at Investor's Business Daily
May-19-15 01:54PMCode Rebel Completes Initial Public Offering and Begins Trading on NASDAQ Capital Market Marketwired
Code Rebel Corporation develops, markets, and licenses its interactive remote application terminal services solution (iRAPP). Its iRAPP allows personal computers (PCs) users to use applications on a single Mac remote desktop simultaneously via the iRAPP client or any standard compliant remote desktop protocol client. The company offers iRAPP client-side products, which allow an end user to connect from a PC to a Mac remote desktop within the Windows environment; terminal services products that enable a large number of end users to remotely access Mac computer applications and data stored on a central management server from various computer and mobile electronic devices; and access products, which provide additional connectivity and functionality to its terminal services products. Code Rebel Corporation was founded in 2007 and is based in Kahului, Hawaii.
1 2 3 4 5 6 ... 10 ... 18 next